Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

KEYNOTE-365 Cohort A: Pembrolizumab plus olaparib in docetaxel-pretreated...

Prof Evan Yu - Fred Hutchinson Cancer Research Center, Seattle, USA

KEYNOTE-365 Cohort A: Pembrolizumab plus olaparib in docetaxel-pretreated patients with mCRPC ( Prof Evan Yu - Fred Hutchinson Cancer Research Center, Seattle, USA )

Adjuvant sequential chemotherapy plus radiotherapy for LABC after radical...

Prof Brian Baumann - Washington University in St. Louis, St. Louis, USA

Adjuvant sequential chemotherapy plus radiotherapy for LABC after radical cystectomy: Urothelial carcinoma subgroup analysis ( Prof Brian Baumann - Washington University in St. Louis, St. Louis, USA )

CheckMate 214: Nivolumab, ipilimumab or sunitinib in patients with advanced...

Prof Nizar Tannir - MD Anderson Cancer Center, Houston, USA

CheckMate 214: Nivolumab, ipilimumab or sunitinib in patients with advanced renal cell carcinoma ( Prof Nizar Tannir - MD Anderson Cancer Center, Houston, USA )

ASCO GU 2019: Updates on treatment and management of bladder cancer

Professor Matthew Galsky, Professor Ananya Choudhury, Professor Joaquim...

ASCO GU 2019: Updates on treatment and management of bladder cancer ( Professor Matthew Galsky, Professor Ananya Choudhury, Professor Joaquim Bellmunt, Dr Andrea Necchi )

ASCO GU 2019: Updates on non-metastatic castration-resistant prostate cancer

Prof Karim Fizazi, Dr Eleni Efstathiou, Prof Boris Hadaschik, Prof Nicholas...

ASCO GU 2019: Updates on non-metastatic castration-resistant prostate cancer ( Prof Karim Fizazi, Dr Eleni Efstathiou, Prof Boris Hadaschik, Prof Nicholas Mottet )

STREAM trial: Enzalutamide and androgen deprivation therapy with salvage...

Prof Andrew Armstrong - Duke Cancer Institute, Durham, USA

STREAM trial: Enzalutamide and androgen deprivation therapy with salvage radiation in men with high-risk PSA recurrent PC ( Prof Andrew Armstrong - Duke Cancer Institute, Durham, USA )

Analysis of acute toxicity from PACE-B: Comparing SBRT to CFMHRT for localised...

Dr Nicholas van As - The Royal Marsden NHS Foundation Trust, London, UK

Analysis of acute toxicity from PACE-B: Comparing SBRT to CFMHRT for localised prostate cancer ( Dr Nicholas van As - The Royal Marsden NHS Foundation Trust, London, UK )

Updates on metastatic bladder cancer from ASCO GU 2019

Prof Arlene Siefker-Radtke - MD Anderson Cancer Center, Houston, USA

Updates on metastatic bladder cancer from ASCO GU 2019 ( Prof Arlene Siefker-Radtke - MD Anderson Cancer Center, Houston, USA )

KEYNOTE-426: Pembrolizumab and axitinib vs sunitinib in advanced renal cell...

Prof Brian Rini - Cleveland Clinic, Cleveland, USA

KEYNOTE-426: Pembrolizumab and axitinib vs sunitinib in advanced renal cell carcinoma ( Prof Brian Rini - Cleveland Clinic, Cleveland, USA )

ASCO GU 2019 renal highlights

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

ASCO GU 2019 renal highlights ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

ARCHES trial: Androgen deprivation therapy with enzalutamide or placebo in mHSPC

Prof Andrew Armstrong - Duke Cancer Institute, Durham, USA

ARCHES trial: Androgen deprivation therapy with enzalutamide or placebo in mHSPC ( Prof Andrew Armstrong - Duke Cancer Institute, Durham, USA )

Latest from Tivo-3: Tivozanib for refractory advanced renal cell carcinoma

Prof Brian Rini - Cleveland Clinic, Cleveland, USA

$Latest from Tivo-3: Tivozanib for refractory advanced renal cell carcinoma ( Prof Brian Rini - Cleveland Clinic, Cleveland, USA )$

More from ecancer